Eli Lilly and Company (NYSE:LLY) Shares Sold by Revisor Wealth Management LLC

Revisor Wealth Management LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 707 shares of the company's stock after selling 478 shares during the period. Revisor Wealth Management LLC's holdings in Eli Lilly and Company were worth $551,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Formidable Asset Management LLC grew its holdings in Eli Lilly and Company by 2.0% in the fourth quarter. Formidable Asset Management LLC now owns 9,608 shares of the company's stock valued at $7,417,000 after purchasing an additional 190 shares during the period. Richmond Investment Services LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $424,000. Columbia River Financial Group LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $206,000. North Star Asset Management Inc. grew its stake in Eli Lilly and Company by 2.0% in the 4th quarter. North Star Asset Management Inc. now owns 16,425 shares of the company's stock valued at $12,680,000 after acquiring an additional 325 shares during the period. Finally, Invst LLC increased its holdings in Eli Lilly and Company by 0.5% in the 4th quarter. Invst LLC now owns 5,579 shares of the company's stock worth $4,307,000 after acquiring an additional 27 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LLY. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Stock Down 0.6%

Shares of LLY stock traded down $4.13 during trading hours on Wednesday, reaching $721.09. 1,195,179 shares of the stock were exchanged, compared to its average volume of 3,613,566. The business's fifty day moving average is $784.45 and its two-hundred day moving average is $801.86. The firm has a market capitalization of $683.40 billion, a P/E ratio of 61.53, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.58 earnings per share. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.